Global diabetic neuropathy market Size study, by Disorder Type (autonomic Neuropathy, peripheral Neuropathy, proximal neuropathy and focal Neuropathy) Treatment (drugs, physiotherapy, radiotherapy and others) Distribution Channel (clinics, hospitals and pharmacy) and Regional Forecasts 2018-2025
Global diabetic neuropathy market to reach USD 5.8 billion by 2025.
Global diabetic neuropathy market is valued approximately USD 3.8 billion in 2017 and is anticipated to grow with a healthy growth rate of more than 5.4 % over the forecast period 2018-2025. Key trends in the market is advent of new therapeutics for treatment of neuropathy and favorable reimbursement scenario which is expected to foster the growth of the diabetic neuropathy market. For instance: In 2016 as per the University of Cambridge, researchers have led to the development of a new approach to treatment of neuropathic pain. Further, the project focuses on a novel way of indirectly modulating the effect of the TRPV1, a significant initiator of the sensation of pain. Additionally, the team worked to show the effectiveness of using certain peptides to interface with the function of TRPV1 with an aim to eliminate neuropathic pain. As a result, healthcare institutions would be capable to deliver new therapeutics for treatment of neuropathy.
Key driving factors for the diabetic neuropathy market are rising prevalence of diabetes coupled with the changing lifestyles that results in to unhealthy dietary habits and patterns. According the Health Metrics - American Heart Association, in 2010 the prevalence of diabetes for adults was recorded to be 6.4% globally. This is expected to increase and reach up to 7.7% by the end of 2030, across the globe. Similarly, as per the MRC United Kingdom 2015, the estimated diabetes prevalence for adults between age group of 20-79 worldwide was around 387 million in 2014 which is estimated to reach around 592 million people by 2023. As a result, people suffering from diabetes are prone to nerve damages which are expected to boost the growth of the diabetic neuropathy market during 2018-2025. Furthermore, rise in demand for better neuropathy drugs offer lucrative growth prospects for the diabetic neuropathy market across the globe. However, high cost associated with diabetic neuropathy along with the side effects of the drugs are expected to hinder the growth of the market during the forecast period.
On the basis of segmentation, the diabetic neuropathy market is segmented into disorder type, treatment and distribution channel. The disorder type segment of global Diabetic neuropathy market is classified into autonomic Neuropathy, peripheral neuropathy, proximal neuropathy and focal neuropathy of which proximal neuropathy dominates the market as it is the most commonly found disorder in type 2 diabetes. On the basis of treatment segment, the market is classified into drugs, physiotherapy, radiotherapy and others. The distribution channel segment is classified into clinics, hospitals and pharmacy.
The regional analysis of diabetic neuropathy market is considered for the key regions such as North America, Europe, Asia Pacific, Latin America and ROW. North America holds the leading position in diabetic neuropathy market owing to the increase in prevalence of diabetes, improved healthcare infrastructure along with the rise in research and development activities. Whereas, Asia-Pacific is expected to emerge as the fastest growing region in terms of market share. The growth of Asia-Pacific is witnessed owing to increase R&D activities for drug discovery along with increasing aging population. Also, improving healthcare infrastructure and services in rural areas is also expected to supplement the growth of Asia-Pacific over the forecast period.
The leading market players include-
By Disorder Type
Global diabetic neuropathy market is valued approximately USD 3.8 billion in 2017 and is anticipated to grow with a healthy growth rate of more than 5.4 % over the forecast period 2018-2025. Key trends in the market is advent of new therapeutics for treatment of neuropathy and favorable reimbursement scenario which is expected to foster the growth of the diabetic neuropathy market. For instance: In 2016 as per the University of Cambridge, researchers have led to the development of a new approach to treatment of neuropathic pain. Further, the project focuses on a novel way of indirectly modulating the effect of the TRPV1, a significant initiator of the sensation of pain. Additionally, the team worked to show the effectiveness of using certain peptides to interface with the function of TRPV1 with an aim to eliminate neuropathic pain. As a result, healthcare institutions would be capable to deliver new therapeutics for treatment of neuropathy.
Key driving factors for the diabetic neuropathy market are rising prevalence of diabetes coupled with the changing lifestyles that results in to unhealthy dietary habits and patterns. According the Health Metrics - American Heart Association, in 2010 the prevalence of diabetes for adults was recorded to be 6.4% globally. This is expected to increase and reach up to 7.7% by the end of 2030, across the globe. Similarly, as per the MRC United Kingdom 2015, the estimated diabetes prevalence for adults between age group of 20-79 worldwide was around 387 million in 2014 which is estimated to reach around 592 million people by 2023. As a result, people suffering from diabetes are prone to nerve damages which are expected to boost the growth of the diabetic neuropathy market during 2018-2025. Furthermore, rise in demand for better neuropathy drugs offer lucrative growth prospects for the diabetic neuropathy market across the globe. However, high cost associated with diabetic neuropathy along with the side effects of the drugs are expected to hinder the growth of the market during the forecast period.
On the basis of segmentation, the diabetic neuropathy market is segmented into disorder type, treatment and distribution channel. The disorder type segment of global Diabetic neuropathy market is classified into autonomic Neuropathy, peripheral neuropathy, proximal neuropathy and focal neuropathy of which proximal neuropathy dominates the market as it is the most commonly found disorder in type 2 diabetes. On the basis of treatment segment, the market is classified into drugs, physiotherapy, radiotherapy and others. The distribution channel segment is classified into clinics, hospitals and pharmacy.
The regional analysis of diabetic neuropathy market is considered for the key regions such as North America, Europe, Asia Pacific, Latin America and ROW. North America holds the leading position in diabetic neuropathy market owing to the increase in prevalence of diabetes, improved healthcare infrastructure along with the rise in research and development activities. Whereas, Asia-Pacific is expected to emerge as the fastest growing region in terms of market share. The growth of Asia-Pacific is witnessed owing to increase R&D activities for drug discovery along with increasing aging population. Also, improving healthcare infrastructure and services in rural areas is also expected to supplement the growth of Asia-Pacific over the forecast period.
The leading market players include-
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Eli Lilly and Company
- Cephalon, Inc.
- ACTAVIS
- GlaxoSmithKline
- MEDA Pharma GmbH & Co. KG
- NeuroMetrix, Inc
- Abbott Laboratories
- Lupin Limited
By Disorder Type
- Autonomic Neuropathy
- Peripheral Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- Drugs
- Physiotherapy
- Radiotherapy
- Others
- Clinics
- Hospitals
- Pharmacy
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- ROE
- Asia Pacific
- China
- India
- Japan
- ROAPEC
- LAMEA
- Brazil
- Mexico
- ROW
- Middle East & Africa
- Historical year – 2015, 2016
- Base year – 2017
- Forecast period – 2018 to 2025
- Key Consulting Companies & Advisors
- Large, medium-sized, and small enterprises
- Venture capitalists
- Value-Added Resellers (VARs)
- Third-party knowledge providers
- Investment bankers
- Investors
CHAPTER 1. GLOBAL DIABETIC NEUROPATHY MARKET DEFINITION AND SCOPE
1.1. Research Objective
1.2. Market Definition
1.3. Scope of The Study
1.4. Years Considered for The Study
1.5. Currency Conversion Rates
1.6. Report Limitation
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Data Mining
2.1.2. Analysis
2.1.3. Market Estimation
2.1.4. Validation
2.1.5. Publishing
2.2. Research Assumption
CHAPTER 3. EXECUTIVE SUMMARY
3.1. Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Billion)
3.2. Key Trends
CHAPTER 4. GLOBAL DIABETIC NEUROPATHY MARKET DYNAMICS
4.1. Growth Prospects
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Industry Analysis
4.2.1. Porter’s 5 Force Model
4.2.2. PEST Analysis
4.2.3. Value Chain Analysis
4.3. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL DIABETIC NEUROPATHY MARKET, BY DISORDER TYPE
5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Global Diabetic Neuropathy Market, Sub Segment Analysis
5.3.1. Autonomic Neuropathy
5.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
5.3.2. Peripheral Neuropathy
5.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
5.3.3. Proximal Neuropathy
5.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
5.3.4. Focal Neuropathy
5.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.3.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 6. GLOBAL DIABETIC NEUROPATHY MARKET, BY TREATMENT
6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Global Diabetic Neuropathy Market, Sub Segment Analysis
6.3.1. Drugs
6.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.3.2. Physiotherapy
6.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.3.3. Radiotherapy
6.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.3.4. Others
6.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.3.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 7. GLOBAL DIABETIC NEUROPATHY MARKET, BY DISTRIBUTION CHANNEL
7.1. Market Snapshot
7.2. Market Performance - Potential Model
7.3. Global Diabetic Neuropathy Market, Sub Segment Analysis
7.3.1. Clinics
7.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.2. Hospitals
7.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.3. Pharmacy
7.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 8. GLOBAL DIABETIC NEUROPATHY MARKET, BY REGIONAL ANALYSIS
8.1. Diabetic Neuropathy Market, Regional Market Snapshot (2015-2025)
8.2. North America Diabetic neuropathy Market Snapshot
8.2.1. U.S.
8.2.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.2.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.2. Canada
8.2.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.2.2.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.2.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.2.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3. Europe Diabetic Neuropathy Market Snapshot
8.3.1. U.K.
8.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.3.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.2. Germany
8.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.3.2.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.2.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.2.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.3. Rest of Europe
8.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.3.3.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.3.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.3.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4. Asia Diabetic Neuropathy Market Snapshot
8.4.1. China
8.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.4.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.2. India
8.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.4.2.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.2.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.2.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.3. Japan
8.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.4.3.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.3.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.3.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.4. Rest of Asia Pacific
8.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.4.4.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.4.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.4.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5. Latin America Diabetic Neuropathy Market Snapshot
8.5.1. Brazil
8.5.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.5.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.2. Mexico
8.5.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.5.2.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.2.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.2.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.6. Rest of The World
8.6.1. Middle East and Africa
8.6.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.6.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.6.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.6.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Company Market Share (Subject to Data Availability)
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Pfizer Inc.
9.3.1.1. Overview
9.3.1.2. Financial (Subject to Data Availability)
9.3.1.3. Product Summary
9.3.1.4. Recent Developments
9.3.2. Janssen Pharmaceuticals, Inc.
9.3.3. Eli Lilly and Company
9.3.4. Cephalon, Inc.
9.3.5. ACTAVIS
9.3.6. GlaxoSmithKline
9.3.7. MEDA Pharma GmbH & Co. KG
9.3.8. NeuroMetrix, Inc
9.3.9. Abbott Laboratories
9.3.10. Lupin Limited
1.1. Research Objective
1.2. Market Definition
1.3. Scope of The Study
1.4. Years Considered for The Study
1.5. Currency Conversion Rates
1.6. Report Limitation
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Data Mining
2.1.2. Analysis
2.1.3. Market Estimation
2.1.4. Validation
2.1.5. Publishing
2.2. Research Assumption
CHAPTER 3. EXECUTIVE SUMMARY
3.1. Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Billion)
3.2. Key Trends
CHAPTER 4. GLOBAL DIABETIC NEUROPATHY MARKET DYNAMICS
4.1. Growth Prospects
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Industry Analysis
4.2.1. Porter’s 5 Force Model
4.2.2. PEST Analysis
4.2.3. Value Chain Analysis
4.3. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL DIABETIC NEUROPATHY MARKET, BY DISORDER TYPE
5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Global Diabetic Neuropathy Market, Sub Segment Analysis
5.3.1. Autonomic Neuropathy
5.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
5.3.2. Peripheral Neuropathy
5.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
5.3.3. Proximal Neuropathy
5.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
5.3.4. Focal Neuropathy
5.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.3.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 6. GLOBAL DIABETIC NEUROPATHY MARKET, BY TREATMENT
6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Global Diabetic Neuropathy Market, Sub Segment Analysis
6.3.1. Drugs
6.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.3.2. Physiotherapy
6.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.3.3. Radiotherapy
6.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.3.4. Others
6.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.3.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 7. GLOBAL DIABETIC NEUROPATHY MARKET, BY DISTRIBUTION CHANNEL
7.1. Market Snapshot
7.2. Market Performance - Potential Model
7.3. Global Diabetic Neuropathy Market, Sub Segment Analysis
7.3.1. Clinics
7.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.2. Hospitals
7.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.3. Pharmacy
7.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 8. GLOBAL DIABETIC NEUROPATHY MARKET, BY REGIONAL ANALYSIS
8.1. Diabetic Neuropathy Market, Regional Market Snapshot (2015-2025)
8.2. North America Diabetic neuropathy Market Snapshot
8.2.1. U.S.
8.2.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.2.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.2. Canada
8.2.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.2.2.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.2.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.2.2.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3. Europe Diabetic Neuropathy Market Snapshot
8.3.1. U.K.
8.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.3.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.2. Germany
8.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.3.2.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.2.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.2.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.3. Rest of Europe
8.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.3.3.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.3.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.3.3.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4. Asia Diabetic Neuropathy Market Snapshot
8.4.1. China
8.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.4.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.2. India
8.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.4.2.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.2.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.2.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.3. Japan
8.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.4.3.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.3.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.3.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.4. Rest of Asia Pacific
8.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.4.4.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.4.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.4.4.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5. Latin America Diabetic Neuropathy Market Snapshot
8.5.1. Brazil
8.5.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.5.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.2. Mexico
8.5.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.5.2.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.2.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.5.2.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.6. Rest of The World
8.6.1. Middle East and Africa
8.6.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
8.6.1.2. Disorder Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.6.1.3. Treatment breakdown estimates & forecasts, 2015-2025 (USD Billion)
8.6.1.4. Distribution Channel breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Company Market Share (Subject to Data Availability)
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Pfizer Inc.
9.3.1.1. Overview
9.3.1.2. Financial (Subject to Data Availability)
9.3.1.3. Product Summary
9.3.1.4. Recent Developments
9.3.2. Janssen Pharmaceuticals, Inc.
9.3.3. Eli Lilly and Company
9.3.4. Cephalon, Inc.
9.3.5. ACTAVIS
9.3.6. GlaxoSmithKline
9.3.7. MEDA Pharma GmbH & Co. KG
9.3.8. NeuroMetrix, Inc
9.3.9. Abbott Laboratories
9.3.10. Lupin Limited